NO20092694L - CRTH2 antagonister - Google Patents
CRTH2 antagonisterInfo
- Publication number
- NO20092694L NO20092694L NO20092694A NO20092694A NO20092694L NO 20092694 L NO20092694 L NO 20092694L NO 20092694 A NO20092694 A NO 20092694A NO 20092694 A NO20092694 A NO 20092694A NO 20092694 L NO20092694 L NO 20092694L
- Authority
- NO
- Norway
- Prior art keywords
- methylindolizin
- acetic acid
- fluoro
- methanesulfonylphenylsulfanyl
- acid
- Prior art date
Links
- 102000009389 Prostaglandin D receptors Human genes 0.000 title abstract 2
- 108050000258 Prostaglandin D receptors Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 15
- -1 ethanesulfonylaminobenzensulfonyl Chemical group 0.000 abstract 4
- WYHNNGNYBDGJEL-GFCCVEGCSA-N (2r)-2-[6-fluoro-2-methyl-3-(4-methylsulfonylphenyl)sulfanylindolizin-1-yl]propanoic acid Chemical compound N12C=C(F)C=CC2=C([C@H](C(O)=O)C)C(C)=C1SC1=CC=C(S(C)(=O)=O)C=C1 WYHNNGNYBDGJEL-GFCCVEGCSA-N 0.000 abstract 1
- WYHNNGNYBDGJEL-LBPRGKRZSA-N (2s)-2-[6-fluoro-2-methyl-3-(4-methylsulfonylphenyl)sulfanylindolizin-1-yl]propanoic acid Chemical compound N12C=C(F)C=CC2=C([C@@H](C(O)=O)C)C(C)=C1SC1=CC=C(S(C)(=O)=O)C=C1 WYHNNGNYBDGJEL-LBPRGKRZSA-N 0.000 abstract 1
- BIOUCUATLFYEEP-UHFFFAOYSA-N 2-[3-(2,4-dichlorophenyl)sulfanyl-6-fluoro-2-methylindolizin-1-yl]acetic acid Chemical compound CC=1C(CC(O)=O)=C2C=CC(F)=CN2C=1SC1=CC=C(Cl)C=C1Cl BIOUCUATLFYEEP-UHFFFAOYSA-N 0.000 abstract 1
- KBTSHLSOQLTXAT-UHFFFAOYSA-N 2-[3-(2-chloro-4-methylsulfonylphenyl)sulfanyl-7-cyano-2-methylindolizin-1-yl]acetic acid Chemical compound CC=1C(CC(O)=O)=C2C=C(C#N)C=CN2C=1SC1=CC=C(S(C)(=O)=O)C=C1Cl KBTSHLSOQLTXAT-UHFFFAOYSA-N 0.000 abstract 1
- QMOBLEDGZGIBFK-UHFFFAOYSA-N 2-[3-(4-bromophenyl)sulfanyl-6-fluoro-2-methylindolizin-1-yl]acetic acid Chemical compound CC=1C(CC(O)=O)=C2C=CC(F)=CN2C=1SC1=CC=C(Br)C=C1 QMOBLEDGZGIBFK-UHFFFAOYSA-N 0.000 abstract 1
- LZCKHQFXTXCWOY-UHFFFAOYSA-N 2-[3-(4-ethylsulfonylphenyl)sulfanyl-6-fluoro-2-methylindolizin-1-yl]acetic acid Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1SC1=C(C)C(CC(O)=O)=C2N1C=C(F)C=C2 LZCKHQFXTXCWOY-UHFFFAOYSA-N 0.000 abstract 1
- KOGDQSJSXZLRRR-UHFFFAOYSA-N 2-[3-[(4-chlorophenyl)methyl]-7-cyano-2-methylindolizin-1-yl]acetic acid Chemical compound CC=1C(CC(O)=O)=C2C=C(C#N)C=CN2C=1CC1=CC=C(Cl)C=C1 KOGDQSJSXZLRRR-UHFFFAOYSA-N 0.000 abstract 1
- LWCBXKUBEWWJAM-UHFFFAOYSA-N 2-[6-fluoro-2-methyl-3-[4-methylsulfonyl-2-(trifluoromethyl)phenyl]sulfanylindolizin-1-yl]acetic acid Chemical compound CC=1C(CC(O)=O)=C2C=CC(F)=CN2C=1SC1=CC=C(S(C)(=O)=O)C=C1C(F)(F)F LWCBXKUBEWWJAM-UHFFFAOYSA-N 0.000 abstract 1
- IXSKNUYJVTZORV-UHFFFAOYSA-N 2-[6-fluoro-3-(2-fluoro-4-methylsulfonylphenyl)sulfanyl-2-methylindolizin-1-yl]acetic acid Chemical compound CC=1C(CC(O)=O)=C2C=CC(F)=CN2C=1SC1=CC=C(S(C)(=O)=O)C=C1F IXSKNUYJVTZORV-UHFFFAOYSA-N 0.000 abstract 1
- AALJAMRPEJGLHD-UHFFFAOYSA-N 2-[6-fluoro-3-(4-methoxyphenyl)sulfanyl-2-methylindolizin-1-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1SC1=C(C)C(CC(O)=O)=C2N1C=C(F)C=C2 AALJAMRPEJGLHD-UHFFFAOYSA-N 0.000 abstract 1
- VLXMMSCENQBUOT-UHFFFAOYSA-N 2-[7-chloro-6-fluoro-3-(4-methoxyphenyl)sulfanyl-2-methylindolizin-1-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1SC1=C(C)C(CC(O)=O)=C2N1C=C(F)C(Cl)=C2 VLXMMSCENQBUOT-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2006/004856 WO2008074966A1 (en) | 2006-12-21 | 2006-12-21 | Crth2 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20092694L true NO20092694L (no) | 2009-07-17 |
Family
ID=38313383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20092694A NO20092694L (no) | 2006-12-21 | 2009-07-17 | CRTH2 antagonister |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100010034A1 (pt) |
| EP (1) | EP2094266A1 (pt) |
| JP (1) | JP2010513429A (pt) |
| CN (1) | CN101605544A (pt) |
| AU (1) | AU2006352195A1 (pt) |
| BR (1) | BRPI0622197A2 (pt) |
| CA (1) | CA2673356A1 (pt) |
| EA (1) | EA200970590A1 (pt) |
| IL (1) | IL199430A0 (pt) |
| MX (1) | MX2009006762A (pt) |
| NO (1) | NO20092694L (pt) |
| WO (1) | WO2008074966A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0625842D0 (en) * | 2006-12-22 | 2007-02-07 | Argenta Discovery Ltd | Indolizine derivatives |
| GB0719521D0 (en) * | 2007-10-05 | 2007-11-14 | Argenta Discovery Ltd | Compounds |
| JP5327762B2 (ja) | 2007-12-14 | 2013-10-30 | プルマジェン セラピューティクス（アズマ）リミテッド | インドールおよびその治療的使用 |
| KR20110071122A (ko) * | 2008-11-17 | 2011-06-28 | 에프. 호프만-라 로슈 아게 | 나프틸아세트산 |
| MX2012010820A (es) | 2010-03-22 | 2012-10-10 | Actelion Pharmaceuticals Ltd | Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2. |
| EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
| WO2012140612A1 (en) | 2011-04-14 | 2012-10-18 | Actelion Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| CN104114169A (zh) | 2011-12-16 | 2014-10-22 | 阿托佩斯治疗有限公司 | 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物 |
| CN103373996A (zh) * | 2012-04-20 | 2013-10-30 | 山东亨利医药科技有限责任公司 | 作为crth2受体拮抗剂的二并环衍生物 |
| PH12016501764B1 (en) | 2014-03-17 | 2024-05-17 | Idorsia Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| WO2015140701A1 (en) | 2014-03-18 | 2015-09-24 | Actelion Pharmaceuticals Ltd | Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators |
| WO2017046125A1 (en) | 2015-09-15 | 2017-03-23 | Actelion Pharmaceuticals Ltd | Crystalline forms |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1174124A (en) * | 1967-06-30 | 1969-12-10 | Beecham Group Ltd | Pharmacologically Active Indolizine Compounds |
| GB1268424A (en) * | 1969-10-04 | 1972-03-29 | Beecham Group Ltd | Indolizine derivatives |
| ES421284A1 (es) * | 1973-12-07 | 1976-04-16 | Farmasimes S A | Procedimiento para la preparacion de derivados de acidos pirrocolinaceticos. |
| WO2005040112A1 (en) * | 2003-10-14 | 2005-05-06 | Oxagen Limited | Compounds with pgd2 antagonist activity |
| JP2007508363A (ja) * | 2003-10-14 | 2007-04-05 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| GB2407318A (en) * | 2003-10-23 | 2005-04-27 | Oxagen Ltd | Substituted Indol-3-yl acetic acid derivatives |
| GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
| GB0512944D0 (en) * | 2005-06-24 | 2005-08-03 | Argenta Discovery Ltd | Indolizine compounds |
-
2006
- 2006-12-21 CN CNA200680056911XA patent/CN101605544A/zh active Pending
- 2006-12-21 EA EA200970590A patent/EA200970590A1/ru unknown
- 2006-12-21 AU AU2006352195A patent/AU2006352195A1/en not_active Abandoned
- 2006-12-21 JP JP2009542176A patent/JP2010513429A/ja not_active Withdrawn
- 2006-12-21 US US12/519,979 patent/US20100010034A1/en not_active Abandoned
- 2006-12-21 BR BRPI0622197-1A patent/BRPI0622197A2/pt not_active IP Right Cessation
- 2006-12-21 EP EP06820622A patent/EP2094266A1/en not_active Withdrawn
- 2006-12-21 CA CA002673356A patent/CA2673356A1/en not_active Abandoned
- 2006-12-21 WO PCT/GB2006/004856 patent/WO2008074966A1/en not_active Ceased
- 2006-12-21 MX MX2009006762A patent/MX2009006762A/es not_active Application Discontinuation
-
2009
- 2009-06-18 IL IL199430A patent/IL199430A0/en unknown
- 2009-07-17 NO NO20092694A patent/NO20092694L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2673356A1 (en) | 2008-06-26 |
| EP2094266A1 (en) | 2009-09-02 |
| IL199430A0 (en) | 2010-03-28 |
| BRPI0622197A2 (pt) | 2012-01-03 |
| US20100010034A1 (en) | 2010-01-14 |
| JP2010513429A (ja) | 2010-04-30 |
| MX2009006762A (es) | 2009-08-20 |
| AU2006352195A1 (en) | 2008-06-26 |
| EA200970590A1 (ru) | 2009-12-30 |
| WO2008074966A1 (en) | 2008-06-26 |
| CN101605544A (zh) | 2009-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| MY152062A (en) | Indole derivatives as crth2 receptor antagonists | |
| SI2326621T1 (sl) | Substituirani derivati 1,2,3,4-tetrahidrociklopenta(b)indol-3-il)ocetne kisline, uporabni pri zdravljenju avtoimunskih in vnetnih motenj | |
| UA96459C2 (uk) | 4-заміщені похідні феноксифенілоцтової кислоти | |
| MY155418A (en) | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives | |
| TNSN07325A1 (en) | Pgd2 receptor antagonists for the treatment of inflammatory diseases | |
| EA201590833A1 (ru) | Антитела для лечения и профилактики болезни альцгеймера и их применение | |
| NO20070293L (no) | Aryl-substituerte piperazinderivater | |
| SI1633726T1 (sl) | Derivativi pirimidina, uporabni pri zdravljenju bolezni, posredovanih s crth 2 | |
| IL190338A0 (en) | Biphenyloxyacetic acid derivatives for the treatment of respiratory disease | |
| MX2009011712A (es) | Formulaciones mejoradas de lamotrigina. | |
| EP2402443A3 (en) | Therapeutic uses of inhibitors of rtp801 | |
| CY1120433T1 (el) | Θεραπεια αγωνιστων μελατονινης | |
| EA200801691A1 (ru) | Соль янтарной кислоты 1-[2-(2-хлор-4-{[(r)-2-гидрокси-2-(8-гидрокси-2-оксо-1,2-дигирдохинолин-5-ил)этиламино]метил}-5-метоксифенилкарбамоил)этил]пиперидин-4-илового эфира бифенил-2-илкарбаминовой кислоты и ее применение для лечения легочных расстройств | |
| WO2011008312A3 (en) | Indole and indoline derivatives and methods of use thereof | |
| ATE448219T1 (de) | Neue hydantoinderivate zur behandlung von obstruktiven atemwegserkrankungen | |
| GB2407318A8 (en) | Substituted indol-3-yl acetic acid derivatives | |
| MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| PH12014500079A1 (en) | 6-substituted phenoxychroman carboxylic acid derivatives | |
| ATE510536T1 (de) | Verwendung von 2,5-dihydroxybenzol-derivaten zur behandlung von reaktiven gewebeerkrankungen | |
| WO2009061730A3 (en) | 4 -heteroaryl- substituted phenoxyphenylacetic acid derivatives as pgd2 inhibitors | |
| EA200970590A1 (ru) | Антагонисты crth2 | |
| EA200970875A1 (ru) | Производные индолизинуксусной кислоты в качестве антагонистов crth2 | |
| WO2008112898A3 (en) | Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes | |
| IN2012DN03844A (pt) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |